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Renal injury in diabetes mellitus is an important clinical as
well as biological problem. Approximately 30% of patients with
type I or insulin-dependent diabetes mellitus [1] and 5 to 10% of
patients with type II or non-insulin-dependent diabetes mellitus
[2] will develop chronic renal insufficiency requiring treatment
in an end-stage renal disease program. The mechanism of this
injury, the underlying cause, and the nature of progressive renal
insufficiency are unclear. In general, it has been proposed that
diabetes is predominantly a glomerular disease as there is a
progressive increase in urinary albumin excretion from 15 to 30
gImin up to nephrotic range proteinuria over 5 to 12 years,
followed by hypertension and decline in glomerular filtration
rate (GFR) after a mean duration of 17 years of diabetes in the
segment of patients at risk. The pathologic lesion of diffuse
glomerular sclerosis or nodular intercapillary glomerular scle-
rosis is typically seen in biopsies from patients with advanced
diabetic nephropathy [3, 4]. Moreover, Mauer and colleagues
[5] and Osterby and Gunderson [6] have shown that there is a
close correlation between the expansion of the glomerular
mesangium and the declining filtration surface area, as well as
the declining GFR in affected patients. These results support
the view of diabetic nephropathy as a primary glomerular and
perhaps primary mesangial disorder.
However, a number of contradictory observations suggest a
potentially important role for alterations in non-glomerular
structures which reside within the renal interstitium in the
development of renal insufficiency in patients with diabetes
mellitus. The following discussion will review the evidence for
a role of altered structure and function of the renal tubulointer-
stitium in diabetes, and propose the hypotheses that altered
tubular transport and metabolic activity contributes to protein-
uria and altered renal hemodynamics in diabetes, and that
interstitial fibrosis plays an important role in the ultimate
expression of renal insufficiency in diabetic nephropathy. We
will discuss several potential mechanisms for these functional
and structural changes and suggest a central pathogenetic role
for hyperglycemia per se in the induction of these abnormali-
ties.
Renal tubular functional changes in diabetes
Tubular proteinuria
Overt diabetic nephropathy is uniformly associated with
excess urinary excretion of protein, often exceeding 2 glday. A
host of functional and structural abnormalities that affect the
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glomerulus in diabetes likely accounts for the enhanced glomer-
ular leakage of plasma proteins. However, during the early
course of the disease, subclinical diabetic proteinuria is the
result of several processes, including increased glomerular
filtration of protein, impairment of tubular reabsorption of
filtered protein and the excretion of proteins which originate
from the tubular epithelium [reviewed in 7]. Thus, in addition to
excess filtration of small amounts of albumin (microalbumin-
uria), the proteinuria of early diabetes is characterized by more
prominent increases in the excretion of low molecular weight
proteins; examples include f32-microglobulin [8—13], retinol-
binding protein, that is, a2-microglobulin [14, 15], N-acetyl-/3-
D-glucosaminidase [14, 16, 17], and several other lysosymes,
ribonucleases and poorly identified peptides [181. In general,
tubular proteinuria of early diabetes is a consequence of an
increased filtered load of protein which exceeds the capacity of
the renal tubule for protein reabsorption [71. However, other
protein moieties which are not filtered but presumably secreted
or shed by the renal tubule may also account for a variable
portion of total urinary protein excretion [7, 14, 16—18].
It should also be noted that impaired tubular reabsorption not
only leads to increased clearance of low molecular weight
proteins but may at least partly be the cause of the early
abnormal urinary excretion of albumin. This is because the
renal tubule can reabsorb significant amounts of filtered albu-
min, and that this capacity may be modified in a dynamic
fashion by a multitude of factors that interfere with tubular
function [7, 181. In other words, it is reasonable to assume that
microalbuminuria is an abnormality in tubular as well as gb-
merular function. However, the exact contribution to the total
amount of albumin excreted which is due to impaired tubular
reabsorption in the diabetic kidney remains to be elucidated.
The mechanisms responsible for the impairment in albumin
(or other protein) reabsorption in diabetes remain poorly under-
stood. Gross structural changes in the renal tubule may not be
evident in the early stages of the disease. Nevertheless, evi-
dence of subtle damage to the renal tubule has been provided by
the finding that the urinary excretion in diabetes of N-acetyl-3-
D-glucosaminidase is markedly increased [14, 16, 17]. This
lysosomal enzyme originating from the proximal tubule cell is
not filtered by the glomerulus but is liberated in the tubular fluid
following proximal tubule injury. The degree of tubular protein-
uria is also correlated with glycemic control [7—9, 11, 16, 19—211;
this implies that reversible tubular dysfunction rather than
irreversible structural changes likely accounts for this response.
Studies in diabetic subjects and in streptozotocin diabetic rats
indicate that poorly-controlled hyperglycemia is associated
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with a marked increase in urinary excretion of low molecular
weight protein (such as p2-microglobulinuria [22—241). When
hyperglycemia is controlled by insulin treatment, excretion of
low molecular weight proteins can be drastically diminished [7,
8, 20, 231 while albumin excretion declines slightly [231. It
should be noted that similar findings also pertain to the genetic
models of diabetic mice [241, suggesting that in streptozotocin-
diabetic rats, tubular proteinuria is not likely to be due to
tubular toxicity of streptozotocin. Therapy of hyperglycemia
and ketoacidosis also diminishes urinary insulin wasting in
children and adolescents with type I diabetes [25, 26]. Thus,
reversible hyperinsulinuria can be added to the manifestations
of tubular proteinuria in diabetes which may reflect functional
changes in the tubular handling of low molecular weight pro-
teins.
Several factors pertinent to glycemic control may modulate
tubular handling of proteins. Increased concentrations of glu-
cose in the glomerular ultrafiltrate may interfere with the
tubular reabsorption of protein directly or indirectly as a
consequence of either osmotic diuresis or the enhanced filtra-
tion rate that causes high urine flow rates [7, 27]. Urinary
protein excretion is directly correlated with glucose excretion
[20, 21, 23, 281. Additional studies are needed to clarify whether
glycosuria interferes with the specific transport capacity of
various proteins. Other potential factors that may contribute to
diabetic proteinuria have not been addressed experimentally
but may include enhanced tubular secretion of protein and
accelerated release of membrane proteins [7]. Abnormal non-
enzymatic glycosylation (glycation) of plasma or membrane
proteins may be responsible for the unusual electrophoretic
pattern of urinary protein in experimental diabetes [22, 29].
Thus, while the microalbuminuria of early diabetes may
represent an abnormality in glomerular barrier function and
may herald or signify the presence of glomerular injury which
will inevitably lead to more substantial degrees of proteinuria
and renal functional impairment, altered tubular handling of
protein may prove to contribute to the development of protein-
uria. The clinical importance of alterations in the tubular
component of protein handling to the prognostic and diagnostic
value of microalbuminuria remains to be defined.
Sodium transport
The induction of diabetes in the experimental animal brings
about an adaptive change in the rates of transport of solutes and
water which maintains the volume and composition of the
extracellular space at a new steady state. During the first few
days of experimental diabetes, excess natriuresis leads to a
negative Na balance [30]. Renal Na wasting results from
hyperfiltration and the osmotic diuresis of glucose as well as
from insulin deficiency, given the stimulatory effects of insulin
treatment on Na reabsorption in the thick ascending limb
[3 1—33] and the proximal tubule [34]. During this early stage, the
contraction of the extracellular fluid volume stimulates mm-
eralocorticoid secretion, which in turn increases Na reabsorp-
tion in the collecting duct, thereby serving to minimize Na
wasting [30, 35, 36]. Additional renal and extrarenal effector
mechanisms are also activated which maintain Na balance. In
fact, as early as three weeks after the onset of experimental
diabetes, Na balance becomes positive and blood volume
increases significantly [30]. Increased food intake, including
Na, may also contribute to Na retention. Furthermore, hyper-
glycemia also induces an osmotic expansion of the extracellular
fluid compartment which partly explains the increase in circu-
lating blood volume [30]. However, it is also evident that
powerful renal adaptive mechanisms contribute to the mainte-
nance of positive Na balance.
In the proximal tubule, Na reabsorption increases propor-
tionately to the increase in GFR, thus maintaining glomerular-
tubular balance [37—39]. The operation of peritubular Starling
forces presumably favors a decrease in the back-leak of fluid via
the paracellular route. Additionally, net transcellular Na reab-
sorption is also stimulated as evidenced by a parallel increase in
the activities of NaIH exchange in the luminal brush-border
membrane [401 and the Na-K-ATPase in the basolateral mem-
brane [35, 36, 41]. Intracellular Na concentration is also signif-
icantly increased implying that the rate of luminal Na entry
exceeds that of basolateral Na exit [42]. Microvillus vesicle
studies demonstrate that the activity of NaJH exchange is
increased in both streptozotocin and autoimmune diabetic rats
[40]. Additionally, as NaHCO3 treatment prevents this stimu-
lation it is concluded that the increase in net acid production
and excretion in diabetes likely stimulate the activity of NaIH
exchange [40]. The stimulation of Na-K-ATPase in the proximal
tubule occurs as early as the first one to two days following the
induction of diabetes and precedes any detectable hyperfiltra-
tion [35, 36]. Moreover, the increase in enzyme activity is not
associated with a concomitant increase per unit weight of
Mg-ATPase or hormone-stimulated adenylate cyclase [36]. The
implication is that generalized tubular hypertrophy is not re-
sponsible for the observed increase in Na-K-ATPase activity.
In fact, it has been hypothesized that tubular hypertrophy may
result from an activation in cellular Na transport such as that
due to an increase in NaJH exchange which is associated with
cellular alkalinization [43] and/or an increase in intracellular Na
concentration [42]. While this contention remains an attractive
hypothesis linking solute transport with the subsequent cellular
events that lead to cell growth, experimental evidence remains
lacking at this time. In fact, in the model of NH3-stimulated
tubular hypertrophy in vitro, the increase in cell mass may
persist even in the absence of stimulated Na/H exchange [44].
Stimulation of Na reabsorption in distal parts of the nephron
also contributes to the maintenance of Na balance in diabetes.
The activity of Na-K-ATPase in the medullary [35,36] and the
cortical [35] thick ascending limb is stimulated, despite insulin
deficiency, presumably due to the increase in the delivery of
solute from the proximal nephron. The Na-K-ATPase activity is
also stimulated in the collecting duct [35,36]. Here, the effect is
most likely due to increased mineralocorticoid secretion as
evidenced by abrogation of stimulation in adrenalectomized
diabetic rats [36]. It should be noted that the stimulation of
Na-K-ATPase in the renal tubule of diabetic animals is seg-
ment-specific. For instance, the activity of the enzyme in the
distal convoluted tubule is not stimulated 135, 36]. Moreover, in
other tissues that may also become targets of diabetic compli-
cations, the activity of Na-K-ATPase may actually be dimin-
ished, such as in glomeruli, in neural and vascular tissues
[45—48].
These actions of hyperglycemia to stimulate Na absorption
and expand the extracellular fluid volume may help induce the
widely recognized stimulation in renal blood flow and rise in
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GFR in diabetes, and could contribute to the deleterious
increase in systemic blood pressure which is seen later in the
disorder. Additionally, pathophysiologic responses in tubular
transport function in diabetes are linked to, or at least associ-
ated with, recognizable structural changes including the induc-
tion of cellular hypertrophy.
Glucose transport
Net proximal glucose reabsorption is predominantly deter-
mined by the activity of Nat-glucose cotransport in the luminal
brush-border membrane and the magnitude of paracellular
back-leak of fluid from the peritubular region into the tubule
lumen [49—51]. Net glucose reabsorption has been shown to
increase proportionately with GFR [50, 51], and delivery rate
[37]. Thus, with the development of hyperglycemia, combined
with the hyperfiltration, the delivery of increased amounts of
glucose in the filtrate is associated with a marked increase in the
absolute rate of reabsorption of glucose in the proximal tubule
[37, 52], reflecting the maintenance of glomerular-tubular bal-
ance for glucose [37, 39, 49]. Presumably, the development of
renal tubular hypertrophy implies an increased capacity for net
glucose reabsorption [531 mediated by an increase in the num-
ber of Natglucose carriers. However, the intrinsic activity of
the Na-g1ucose cotransporter measured in microvillus mem-
brane vesicles is actually decreased in experimental models of
diabetes [40]. As a result, it is likely that the observed increase
in net glucose transport in vivo may result from the marked
increase in filtered glucose load despite a decrease in intrinsic
carrier-mediated transport [40]. The decrement in Nat-glucose
carrier activity can be restored to normal following insulin
treatment and lowering of plasma glucose levels to near-normal
[40]. In these studies, neither the affinity nor the binding
number of the carrier is significantly altered in the diabetic
animals with or without insulin treatment compared with nor-
mal animals. Thus, it was postulated that the activity of
Natglucose carriers was modulated by the alterations in the
mobility of the transporters in their lipid domains [54], or due to
protein glycation [55].
It should be noted that in contrast to the diabetic hyperfiltra-
tion which is associated with a decrease in the Nat-glucose
carrier activity, hyperfiltration induced by high protein feeding
is not associated with changes in Nat-dependent glucose trans-
port in membrane vesicles [561. Thus, it is possible that in
diabetes, insulin deficiency and/or hyperglycemia per se medi-
ate the decrease in transporter activity. Baum has recently
demonstrated that physiologic concentrations of insulin added
to the peritubular bath of microperfused rabbit proximal tubules
stimulate fluid reabsorption directly even in the absence of
luminal glucose [34]. Net glucose reabsorption is also signifi-
cantly stimulated by insulin addition [34]. Other studies dis-
closed an inverse relationship between ambient glucose con-
centration and Nat-glucose transport activity of the LLC-PK1
cell line [57]. Carrier number determined by phlorizin binding is
decreased when the cells are grown in a high glucose medium.
In this context, it is important to indicate that high glucose
concentrations in culture media exert direct effects in vitro on
the structure and function of proximal tubule cells. For in-
stance, Hazen-Martin et al [58], employing a cell culture model
of human proximal tubule cells, demonstrated that high glucose
alters the ultrastructure of the cells, modifies the intercellular
junctions and reduces dome formation of confluent cell mono-
layers. These studies, along with our findings of the effects of
glucose on proximal tubule growth and extracellular matrix
biosynthesis (see below), emphasize the direct, and potentially
detrimental effects of ambient glucose on cellular structure and
function.
Divalent ions
A high prevalence of osteopenia has been demonstrated in
diabetic patients, in part due to hypercalciuria [59—61]. The
pathogenesis of hypercalciuria appears to be multifactorial.
Hyperfiltration and osmotic diuresis, coupled with hyperphagia
[62], increase urinary calcium excretion [39, 63]. Insulin treat-
ment only partially corrects hypercalciuria [64]. Guruprakash et
al [63] provided evidence for an additional intrinsic impairment
in tubular calcium reabsorption. In vivo microinjection studies
disclosed defective tubular reabsorption of calcium in the loop
of Henle (presumably in the thick ascending limb) and in the
terminal regions of the nephron [631 which could not be
attributed to a defect in PTH secretion or action, or to an
increased intake of calcium.
Patients with type I (insulin-dependent) diabetes mellitus
have increased fasting urinary excretion of phosphate related to
a decrease in the maximal capacity of the renal tubular reab-
sorption of phosphate per unit filtrate [39, 65, 66]. These tubular
abnormalities are also reversible and probably relate to subop-
timal blood glucose control [39, 65]. The phosphaturia in
diabetes is not due to defects in PTH or growth hormone action
as the levels of these hormones are reported to be not different
form nondiabetic subjects [65].
Despite hyperfiltration, proximal tubular reabsorption of
phosphate is not concomitantly increased. This implies that for
phosphate, in contrast to Na and glucose, glomerular-tubular
balance is disrupted [39, 65]. As both glucose and phosphate
transport in the proximal tubules are coupled to active Na
transport, it is likely that glucose reabsorption interferes with
phosphate transport by inhibiting phosphate affinity at the
tubular brush-border membrane. Glucose infusions sufficient to
cause glycosuria result in a reduction in phosphate reabsorption
[67]. This response is not due to a nonspecific osmotic intralu-
minal effect since mannitol infusion does not alter phosphate
reabsorption [67].
Summary
A variety of functional alterations in the tubulointerstitium
have been described in diabetes. The clearest area of patho-
physiologic importance is the contribution to increased rates of
protein excretion (microalbuminuria) which may result from
altered proximal tubular handling of proteins in diabetes. The
role of this abnormality in producing microalbuminuria has not
been fully elucidated; such tubular changes could help explain
the finding that microalbuminuria may be dissociated from
specific changes in glomerular structure in early clinical diabe-
tes mellitus [68]. The increase in extracellular fluid volume in
diabetes may also result in large part from enhanced tubular
sodium reabsorption; this could contribute to the hypertension
which is typical of advanced diabetic nephropathy. However,
the relationship between these functional changes, renal hyper-
trophy, and later tubulointerstitial injury remains unknown. In
the following discussion, the disturbances of the renal tubu-
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lointerstitial structure in diabetes will be detailed, and several
potential mechanisms for these abnormalities will be reviewed.
Renal tubulointerstitial structural changes in diabetes
The pathology of advanced diabetic nephropathy has been
extensively reviewed [69], and most workers have emphasized
the evolution of glomerular abnormalities leading to the ulti-
mate development of diffuse glomeruloscierosis. In general, a
large proportion of patients, including many without signs of
clinical diabetic nephropathy have, on renal biopsy, glomerular
basement membrane thickening as well as mild to moderate
degrees of expansion of basement membrane-like material in
the mesangium [68]. As microalbuminuria and later, as overt
nephropathy develop, these lesions typically become more
marked. "Cross sectional" studies of patients with various
levels of GFR have been used to support the hypothesis that the
progressive expansion of the glomerular mesangium is accom-
panied by a progressive decline in GFR, as filtering surface is
compromised by the mesangial-basement membrane-like mate-
rial accumulation [5].
Studies of the earlier stages of renal involvement in diabetes
have yielded conflicting information regarding the specificity of
these glomerular changes. In these latter studies, the amount of
glomerular mesangial expansion was generally more extensive
in those patients with hypertension, overt proteinuria, and
declining GFR [5]. However, at earlier points in the evolution of
diabetic nephropathy, there may be marked glomerular mesan-
gial expansion and capillary basement membrane thickening [6,
68]. If glomerular mesangial expansion is the hallmark patho-
logic lesion of diabetic nephropathy, it is unclear why a large
fraction of these patients with abnormal glomerular pathology,
and specifically mesangial expansion, will demonstrate this
histologic finding without expressing fixed microalbuminuria of
more than 30 sg/min [5, 69]; microalbuminuria of this degree
has been shown in several longitudinal studies [70—73] to
accurately predict the later development of overt diabetic
nephropathy. If patients without microalbuminuria have mesan-
gial expansion yet only those patients with microalbuminuria
will go on to develop nephropathy, it is uncertain that glomer-
ular mesangial expansion is actually responsible for altered
glomerular function. Whether all patients with mesangial ex-
pansion will eventually develop microalbuminuria and go on to
overt nephropathy has yet to be shown.
This uncertainty over the relationship between glomerular
mesangial expansion and microalbuminuria has led some work-
ers to question whether the early glomerular histopathologic
lesions in diabetes actually are responsible for the later func-
tional deterioration [74]. This uncertainty and the observation
that decline in GFR in patients with diabetes is also correlated
with intrarenal vascular lesions [74], and with interstitial fi-
brosis [75] leads to a reconsideration of the nature of renal
injury in diabetes, at least with regard to the factors that
determine advanced renal failure.
Arteriosclerosis and renal injury in diabetes
In a variety of tissues in patients with diabetes, a form of
ischemic injury induced by exudative hyalinosis which progres-
sively obliterates small and medium sized arterioles may be
responsible for functional organ failure. In nerve, heart, and
distal portions of the extremities, ischemic injury has been
hypothesized. The potential role of such a vascular lesion in the
kidney in advanced nephropathy seems likely [74, 75].
As renal function deteriorates, progressive obliteration of
glomeruli occurs, and this clearly plays an important role in
reducing total kidney GFR [76]. Osterby and co-workers have
suggested that this pathologic entity occurs in a peculiar colum-
nar-like pattern of distribution within all levels of the renal
cortex [76]. This in turn suggested a vascular component to the
phenomenon of glomerular occlusion as these "columns" cor-
responded to the distribution of large renal interlobular vessels.
Vascular occlusion in medium-sized renal vessels could predis-
pose to glomerular occlusion and nephron destruction charac-
terized by afferent arteriole exudative hyalinosis. Deckert and
colleagues examining biopsies of 44 patients with various stages
of diabetic nephropathy have also found that an arteriopathy is
an important characteristic of the kidney in advanced diabetic
nephropathy [74].
The role of arteriolar lesions in inducing diabetic changes has
been implied from several observations. First, Bader et al [75]
in biopsies from patients with diabetic nephropathy have found
a clear correlation between the degree of diabetic glomerulo-
sclerosis and a quantitative index of arteriolar hyalinization and
occlusion. It was clear from these observations that the degree
of vessel obstruction and obliteration was inversely correlated
with the level of renal function and directly correlated with the
greater severity of both diabetic glomerular sclerosis and inter-
stitial fibrosis. Similarly, Deckert et al [743 found that arteriolar
hyalinosis tended to be more severe in patients with overt
nephropathy and increased interstitial tissue volume, but this
abnormality was also found in patients with milder forms of
nephropathy and, therefore, could not be used to distinguish
those individuals with more severe lesions. However, the fact
that 20% of glomeruli were totally occluded in patients with
overt nephropathy whereas less than 10% of glomeruli were
occluded in the less severely affected group suggests that
vascular occlusion could represent an important mechanism of
the loss of glomeruli in the more severely affected individuals.
In summary, direct arteriolar obliteration could play an
important role in the progressive renal failure of diabetic
nephropathy through producing glomerular occlusion or
through producing chronic tubulointerstitial ischemia and
thereby stimulating interstitial fibrosis. As noted below, the
latter may also be a primary event related to the direct biochem-
ical effects of sustained hyperglycemia.
Tubulointerstitial fibrosis
Interstitial fibrosis could originate from non-vascular injury
and be a primary abnormality in diabetic nephropathy. Bohie
and colleagues have suggested that changes in the renal inter-
stitium may represent the crucial parameter that produces renal
failure in a variety of renal diseases as well as in diabetes
[77—79]. This hypothesis derives from a histomorphometric
study of biopsies of 105 patients with various degrees of
diabetic nephropathy. In this study, there was a striking corre-
lation between the percent of kidney volume occupied by the
renal interstitium and the decline in GFR as measured by serum
creatinine level [75]. As shown in Figure 1, the relationship
exists over a wide range of serum creatinine values.
Also, there is a strong direct correlation between the inter-
stitial expansion and the progression of glomerular sclerosis.
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This could suggest a parallel process damaging the glomeruli
and tubulointerstitial structures, or the changes in the intersti-
tium could be initiating a secondary glomerular process as will
be discussed below. Mauer and colleagues [51 have also ob-
served similar relationships as indicated in Figure 2. In their
large study of the histomorphometry of renal biopsies from
patients with diabetes mellitus, interstitial fibrosis was evident
even at the earliest stages of diabetic nephropathy, although it
was subtle and required careful examination for its detection.
As glomerular filtration fell, the interstitial fibrosis became
much more prominent.
Bader and colleagues proposed that the interstitial fibrosis of
diabetes could be directly responsible for producing both the
declines in glomerular filtration as well as contribute to the
structural glomerulopathy through a number of possible mech-
anisms [75]. First, progressive expansion of the renal intersti-
tium could lead to a progressive obliteration of vascular ele-
ments and thus induce an ischemic nephropathy. This could
also contribute to the process of the glomerular occlusion which
characterizes the later phases of diabetic nephropathy. In
addition, the increased interstitial fibrosis could not only lead to
increased resistance or at least reduced compliance in the pre-
and in the post-glomerular vessels, but could also potentiate the
transmission of systemic hypertension to glomerular structures
by impairing vascular autoregulation. Such changes could con-
tribute to glomerular hypertension observed in experimental
animals with diabetes. Also, to the extent that tubular obstruc-
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tion could result from interstitial fibrosis, increased intratubular
pressure could lead to progressive glomerular injury. Finally, if
tubular dropout occurs, GFR would be eliminated in an affected
nephron and thereby contribute to a decline in total number of
functioning nephrons.
Abnormalities in renal tubulointerstitial structures have also
been observed in experimental diabetes in animals. Weil et a!
[801 showed that after four months of experimental diabetes
induced by streptozotocin infusion in rats, there was a progres-
sive tubulopathy characterized by the accumulation of myeloid-
like bodies in the proximal tubular cells with progressive
tubular disruption. Rasch [81] has also studied the pathology of
short-term streptozotocin diabetic rats in order to investigate
the site and mechanism of the Ebstein-Armanni lesion, an
accumulation of PAS-positive material in renal tubular cells.
She determined that this material is glycogen which accumu-
lates predominantly in distal nephron and ascending limb cells.
However, the pathophysiologic importance of glycogen accu-
mulation in both cytoplasm and the nuclei of these epithelial
cells or myeloid bodies remains to be determined.
We (unpublished observations) and others [82] have investi-
gated the long-term changes in the renal interstitium in diabetes
and have discovered tubulointerstitial changes which occur
after six to nine months of sustained hyperglycemia in strepto-
zotocin-treated rats. On a grading scale ranging from 1 to 4
assaying for the presence of interstitial fibrosis, tubular cell
atrophy, interstitial inflammatory infiltrates, or tubular dilation,
we found that 11 of 14 long-term diabetic rats demonstrated
mild interstitial lesions whereas only 3 of 16 age-matched
control animals on a normal diet manifested similar changes
(Table 1). Adler and colleagues also investigated this question
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Fig. 2. Relationship between an index of mesangial expansion, deter-
40 mined by semiquantitarive estimate of mesangial zones in glomeruli,
and an index of interstitial fibrosis determined by a semiquantitative
estimate of the space occupied by fibrous tissue separating cortical
tubules in patients with insulin-dependent diabetic nephropathy of
varying clinical degrees. (From ref. [5]. Reprinted with permission.)
Relative interstitial volume,
%
Fig. 1. Relationship between the serum creatinine concentration (y-
axis) and the percent of renal mass occupied by interstitial tissue
(x-axis) in renal biopsies from patients with diabetes mellitus and
various degrees of nephropathy. Normal (ni) range is indicated by the
square. (Redrawn from Bader et al, ref [75], used with permission.)
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Table 1. Tubulointerstitial lesions in diabetic rats
Experimental
condition
Interstitia1 histopathologic lesions
Present Absent Total
Diabetes iia 3 14
Age matched controls 3 13 16
Fourteen diabetic rats (streptozotocin 60 mg/kg iv.) and sixteen
control diet rats were placed in cages and maintained on ad lib food and
water for 6 to 9 months. Blood glucose was monitored weekly, and
diabetic animals received long acting insulin as a daily injection to
maintain blood glucose between 300 to 400 mg/dl. The animals were
sacrificed at various time points beginning at six months, and kidneys
were examined by standard light microscopic techniques. The renal
interstitium was evaluated in a blinded fashion by a pathologist using a
grading system which assayed the interstitium for the presence of
interstitial fibrosis, tubular atrophy, interstitial cellular infiltrates, or
tubular cell dropout. There was only minimal evidence of any glomer-
ular lesions in these animals at this time point.
P < 0.01, by Exact Probability Test, for the incidence of pathologic
lesions in diabetes vs. control
in nine-month streptozotocin diabetic rats and found tubular
interstitial fibrosis, atrophy, tubular basement membrane thick-
ening, glomerular sclerosis and mild mesangial expansion [821.
Thus, it appears that tubular interstitial changes seen in the
diabetic patients have their experimental analogue in rats ren-
dered diabetic with streptozotocin. Interestingly, glomerular
morphology in the rat with experimental diabetes may not be
analogous to the human counterpart as mesangial expansion is
not typically observed in this model [83].
In summary, while it is unquestioned that changes in the
glomerular mesangium and glomerular capillary basement
membrane in diabetes contribute to microalbuminuria as well as
to the structural changes of progressive diffuse diabetic glomer-
uloscierosis, the contribution of tubulointerstitial changes to the
progressive decline in GFR seems equally likely. This hypoth-
esis may be particularly relevant in explaining how the kidneys
ultimately fail in diabetic nephropathy rather than how the
glomerular morphologic changes develop. The progressiofi
from a normal or a modestly reduced GFR to a level requiring
renal replacement therapy may be critically determined by
these changes described in the tubulointerstitium and vascular
compartments.
Tubulointerstitial infection and papillary necrosis
Pyelonephritis and papillary necrosis are occasionally ob-
served in patients with diabetes mellitus. While these lesions
may be important in any given patient, they are not a common
agent of progressive renal decline. Papillary necrosis is occa-
sionally seen in patients with diabetes and in fact diabetes
mellitus is probably the commonest co-morbid condition re-
ported with papillary necrosis in the literature. For example, in
an autopsy series from Johns Hopkins Hospital [84] diabetes
was found in 44% of 25 cases of papillary necrosis. The
mechanism leading to this lesion is not clear but several
possibilities have been forwarded. First, vascular obstruction
could lead to a reduction of blood flow to the oxygen deficient
renal papilla. This could accelerate an ischemic injury and
induce areas of necrosis in the inner medulla. In addition,
infection may occur more frequently in patients with diabetes
because of glycosuria and diabetic cystopathy. In this circum-
stance, the combination of ischemia induced by vasculopathy
and infection could act in concert to induce papillary necrosis.
Other possibilities include an exaggerated degree of interstitial
fibrosis in the inner medulla which could further compromise
blood flow to the inner portions of the medullary and papillary
regions.
The speculation that "pyelonephritis" in diabetic patients is
attributable to infection is not supported by clinical-pathologi-
cal analyses [85]. Several studies have indicated a rather
modest degree of urinary tract infection or chronic bacteriuria
in patients with diabetes. Rengart [86] suggested that bacteri-
uria was relatively uncommon and occurred in less than 10% of
patients with diabetes. In addition, studies of patients with
bacteriuria suggest that renal function does not necessarily
deteriorate in these individuals [87]. Thus, it is unlikely that the
tendency to demonstrate interstitial fibrosis and inflammation in
patients with diabetes is a secondary manifestation of chronic
infection.
Mechanisms of tubulointerstitial injury in diabetes
Role of altered metabolic milieu
The contribution of the abnormal metabolic milieu of diabe-
tes, particularly hyperglycemia per Se, compared to a genetic
predisposition to altered basement membrane thickness and
composition in diabetes has been vigorously debated [88, 89].
However, it seems clear that the basement membrane abnor-
malities are a function of hyperglycemia rather than a compo-
nent of the genetic predisposition to diabetes. Steffes et al [90],
studied identical twins discordant for diabetes mellitus by
sampling muscle and kidney tissues. In these studies, the
diabetic patients were divided into those with clinical diabetic
nephropathy, diabetes but normal renal function, and those
with diabetes but only minor clinical indications of nephrop-
athy. The non-affected twins had normal glomerular basement
membrane width and normal fractional volumes of the glomer-
ular mesangium as well as tubular basement membranes. Val-
ues for each of these parameters in each diabetic twin exceeded
the value in the respective normal sibling, even if the value in
the diabetic twin lay within the established normal ranges.
Patients with the most severe renal changes had the greatest
degree of difference in the thickening of the capillary basement
membranes. Values for muscle capillary basement membrane
within the diabetic twins did not differ from those in their
siblings. These data suggest that muscle capillary basement
membrane may not be a good index of diabetic involvement in
part because of an inherent variability in this value in normal
individuals. On the other hand, the values in diabetic patients
for the various intrarenal vessels and tubular basement mem-
branes suggest that the renal abnormality requires an abnormal
metabolic milieu and is not an independently inherited abnor-
mality. These data as well as others suggest that changes within
the kidney are likely related to hyperglycemia.
Role of glucose-related injury to the tubulointerstitium
Several possible mechanisms could explain renal interstitial
fibrosis in diabetes. First, as noted above, vascular obstruction
and obliteration could produce ischemic damage in the renal
interstitium; fibrosis could be the result of fibroblast or intersti-
tial cell response to injury. This pathway for injury has been
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alluded to above. The cellular mechanism of the glucose-
induced vascular lesion in diabetes has not been adequately
defined. A number of possible explanations have been sug-
gested including altered blood flow secondary to abnormal
rheostatic properties of red blood cells [91], disturbed platelet
function leading to intravascular coagulation [92, 93], and
primary disturbances in vascular wall function induced by
hyperglycemia [94]. The latter possibility is attractive and has
been extensively studied. Human endothelial cells maintained
in primary culture elaborate increased amounts of basement
membrane-like materials and noncollagenous protein such as
fibronectin compared to cells grown in normal glucose media
[95]. This has led to the hypothesis that glucose directly
influences cell function to increase matrix synthesis and/or
decrease matrix degradation as a mechanism of increased
arterial hyalinosis. This issue will be discussed more fully
subsequently, particularly with respect to the actions of glucose
to increase renal scarring by a direct action on tubulointerstitial
cells.
Nonenzymatic glycation
A series of recent studies have suggested an important role
for the nonenzymatic glycation of various extracellular proteins
in contributing to the altered structure of both vascular tissue as
well as other renal components, including the renal interstitium
when exposed to persistent elevation of extracellular glucose
levels [96, 97]. This metabolic consequence of hyperglycemia
could be an important contributory feature to late tissue damage
in diabetes. Nonenzymatic glycation refers to the condensation
reaction between glucose and free amino acids at the amino
terminus of lysine residues of proteins. The reaction proceeds
through formation of a Schiff base between the carbonyl groups
of glucose and the amino acids. The resulting aldimine linkage
is stabilized by undergoing Amadori rearrangement to form a
ketoamine [98].
Extracellular matrix proteins such as collagens are rich in
lysine and hydroxylysine, have a long biologic half-life, and are
continuously exposed to ambient levels of glucose in the
extracellular fluid [96]. These proteins are good candidates for
undergoing substantial glycation in vivo, and in fact, studies
now demonstrate that there is a two- to threefold increase in the
level of glycation of collagens from tissues of diabetic subjects
or animals compared to controls [99, 100].
The effects of these glycations examined in vitro have in-
cluded resistance to collagenase digestion and interference with
normal cross-link formation [101], and the change in various
physical properties of the molecules such as thermal stability
and tensile strength [102]. Finally, the nonenzymatic glycation
of noncollageneous extracellular matrix proteins which act as
adhesion molecules and help anchor proteoglycans such as
heparan sulfate [1031 to basement membranes, and thereby
influence the electrical charge of the basement membrane, may
also have important functional consequences. Loss of charge
may contribute to the penetration of circulating proteins into
the basement membrane and ultimately to proteinuria.
Whether these relatively acute actions of high glucose to
induce nonenzymatic glycation ultimately produce the struc-
tural damage seen in long-standing diabetes is uncertain. The
need to relate the lengthy interval between onset of diabetes
and clinical manifestation of structural and functional abnor-
malities has led to the study of the role of later-developing
advanced glycosylated end-products (AGE's), which may take
months or even years to develop, in producing diabetic injury
[104]. These advanced glycosylation end-products create ex-
tremely abnormal matrix proteins which have been shown to be
capable of trapping albumin within basement membranes, trap-
ping lgG in extracellular matrix, and decreasing the solubility of
the now abnormally linked collagens [105].
Thus, the increased fibrosis and exudative vascular hyali-
noses which characterize long-standing diabetes in experimen-
tal animals as well as in patients could in part be a function of
chronic exposure of these proteins to high ambient glucose
levels and subsequent nonenzymatic glycation forming both
short-lived as well as long-lived glycation products. These
products may not only produce progressive vascular occlusions
but also may cause the accumulation of matrix components in
the interstitium producing interstitial fibrosis and secondary
glomerular, tubular, and vascular injury.
The proof of the importance of this protein glycation pathway
for the production of fibrosis in vivo awaits studies in which
pharmacologic manipulation of these AGE's and their cross
linking is accomplished. Preliminary data using aminoguanidine
has suggested that this compound, through interacting with the
reactive amino groups in preventing the formation of glucose-
dependent cross links, will reduce the structural change of
glomerular basement membrane thickening in experimental
diabetes [105].
Alterations in extracellular matrix synthesis and degradation
Studies of the alterations of extracellular matrix metabolism
in diabetes all suggest that there is an increased production and
reduced degradation; both processes may contribute to extra-
cellular matrix accumulation. A number of observations in
various tissues suggest that both animals with experimental
diabetes and patients have an increased synthesis of a variety of
extracellular matrix components, including type IV [1061 and
Type I collagens [107], as well as various noncollagenous
proteins such as laminin [108]. Vascular hyalinosis and intersti-
tial fibrosis could result from the actions of glucose to stimulate
biosynthetic pathways for extracellular matrix systems.
Studies of the effects of diabetes on extracellular matrix
components in the kidney have been primarily devoted to an
examination of changes within the glomerulus. Typically, the
glomerular collagenous mass is increased [107] but whether
there are compositional changes remains a controversial point
[109]. Early studies suggested there were increased concentra-
tions of hydroxy-proline, hydroxylysine and glucosyl-galacto-
syl-hydroxylysine [110]. However, subsequently this was not
confirmed, and Kefalides suggested that increases in hydroxy-
lysine and hexose content of diabetic membranes are accompa-
nied by increases in hydroxy-proline and glycine, all suggesting
an elevated collagen content rather than compositional change
[111].
There is other convincing evidence that glomerular basement
membrane collagen production is increased in experimental
diabetes [109, 112]. Studies have demonstrated augmented
incorporation of labeled proline into hydroxy-proline in diabe-
tes [113], increased uptake of labeled hydroxy-lysine in glomer-
uli, and glomerular basement membrane in experimental diabe-
tes after one to six weeks, and elevation of plasma levels of
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various components of type IV or basement membrane collagen
[113, 114]. Analysis of the activity of several enzymes involved
in collagen synthesis suggests that there is a general tendency
towards increased specific activity of synthesis-related post-
translational enzymes, indicating that enhanced synthetic activ-
ity contributes to the overall increased collagen content [109,
112]. Glycosyltransferase, the most studied enzyme, has been
found to be increased in the renal cortex of animals rendered
diabetic by the infusion of alloxan and in other animal models of
diabetes [115]. In addition, galactosyltransferase activity has
also been reported to be increased after one week of strepto-
zotocin diabetes [113].
Nevertheless, as previously noted, decreased degradation of
glomerular basement membrane glycoproteins has been well
documented in various experimental models of diabetes. For
example, reduced collagenase activity has been reported in
kidneys of streptozotocin diabetic rats [116] and decreased
renal lysosomal enzyme activity has also been reported [117];
each of these findings could contribute to the overall diminution
of the turnover of the glomerular basement membrane.
All of these studies of renal extracellular matrix accumulation
have aimed at defining intraglomerular changes. Virtually no
studies have considered the mechanism of tubulointerstitial
matrix abnormalities. To address this issue, we have recently
developed a model system utilizing proximal tubular cells
maintained in continuous culture in order to study the mecha-
nism of glucose-induced tubulointerstitial fibrosis and extracel-
lular matrix accumulation in diabetes [118—121]. We hypothe-
sized that since the proximal tubular cells constitute the bulk of
cells found in the renal cortex and since renal epithelial cells
have been found to produce matrix components such as type I
and type III interstitial collagens in addition to basement
membrane components such as type IV collagen and laminin
[122], that it is possible that glucose could induce a small
increase in interstitial type collagen synthesis by these cells,
which could lead to an accumulation of collagen in the renal
interstitium. The kidney cell line that we studied is derived from
mouse tubules dissected and transformed with an SV4O, non-
replicating viral strain and maintained in serum-free medium in
order to assay the secretion of collagen [122]. We found that
these cells under the influence of medium glucose level of 450
mg/dl compared to 100 mg/dl, do elaborate increased amounts
of types I and IV collagen [120] (Fig. 3).
In addition, we determined that the increased collagen syn-
thesis is associated with an increase in the mRNA for the al
chain of type IV and the a2 chain of type I collagen, suggesting
the possibility that glucose acts to stimulate gene transcription
or acts to stabilize the messenger RNA synthesized, and
therefore increases its capacity to translate proteins [121, 122].
These data suggest that increased interstitial collagen formation
in diabetes could be the result of a direct effect of glucose on the
proximal tubule cells and need not be solely the result of
ischemia or fibroblast proliferation within the renal paren-
chyma, although these factors may still be important pathoge-
netic mechanisms of interstitial fibrosis.
Recently Adler and colleagues have made similar observa-
tions utilizing in situ hybridization for the type IV collagen
mRNA, and have determined that increased type IV procolla-
gen mRNA is expressed in the straight segment of the proximal
tubule in streptozotocin-diabetic rats [123]. These in vivo and in
0
Fig. 3. Effects of medium glucose concentration on procollagen type 1
and lv secretion by mouse proximal tubular cells in vitro. Open bars
represent cells grown in serum-free medium containing 100 mg/dl
glucose for 48 to 72 hours; shaded bars represent cells grown in 450
mg/dl glucose. Procollagen levels in conditioned supernatants were
measured by a sensitive radioimmunoassay and were expressed per
equivalent numbers of cells (as reflected by 3H-thymidine incorporation(CPM)). There was a significant increase in procollagen type IV
secretion (** = P < 0.01, N = 11) and procollagen type I secretion(* = P < 0.03, N = 17) by cells grown in the high vs. the low glucose
concentration. Note that the cells secrete much greater amounts of type
IV than type I procollagen.
vitro studies are complementary and strongly suggest that one
of the mechanisms of increased interstitial collagen formation in
diabetes could be the result of the direct actions of glucose to
increase collagen gene expression. The cellular mechanism of
this action of glucose remains to be determined.
Hypertrophy of the tubulointerstitium in diabetes
Hypertrophy of the kidney is characteristic of insulin-depen-
dent diabetes and may have important implications in the
ultimate expression of renal structural damage in diabetes.
Renal growth is predominantly the result of cellular hypertro-
phy, and proliferation to a much lesser extent, and clearly
involves the renal tubulointerstitial mass as well as the glomer-
uli [124—128]. In fact, the tubulointerstitium comprises the bulk
of the kidney and is responsible for the largest component of
renal enlargement [124—128]. Kidney RNA content in strepto-
zotocin-induced diabetes rises within 36 hours after the onset of
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hyperglycemia while there is little change in DNA content.
Thereafter, DNA content increases slightly as evidenced by
3H-thymidine incorporation and autoradiographic analyses
[125—127]. The mechanism of this phenomenon is unknown but
clearly represents a direct stimulation of cell growth as there is
an increase in indices of hypertrophy prior to a detectable rise
in measures of renal perfusion [129]. In an in vitro model of
diabetic renal hypertrophy, we recently demonstrated that a
high concentration of medium glucose is a direct stimulus to
promote proximal tubular cell hypertrophy [1201.
The mechanisms mediating renal hypertrophy are discussed
elsewhere in this issue. In diabetes, several postulates have
been considered including glucose-dependent activation of met-
abolic pathways such as increased pentose-phosphate shunt or
stimulation of ammoniagenesis, enhanced solute transport ac-
tivity and hypermetabolism, and/or modulations in the response
to hormones and growth factors [42—45, 124].
Several cytokines have been evaluated in attempts to deter-
mine their role in initiating diabetic renal hypertrophy. IGF- 1 is
a major mediator of growth hormone action. The kidney is a
source of IGF- 1 synthesis as well as a target organ for IGF- 1
action [130, 131]. IGF-1 levels are elevated in some diabetic
patients, particularly those with more severe retinal changes
[132]. Thus, it is possible that IGF-1 is an important contribut-
ing factor to renal hypertrophy in diabetes. However, other
growth factors such as platelet-derived growth factor (PDGF),
transforming growth factor-/3, epidermal growth factor (EGF)
and other known peptjdes involved in stimulating this compo-
nent of cell function could be important mediators of the actions
of glucose.
Many of the growth-promoting factors mentioned above act
to increase mesangial cell proliferation and matrix synthesis and
thus can be readily linked to a stimulation of mesangial expan-
sion and progressive glomerulosclerosis [133]. The importance
of these various growth promoting peptides to induce renovas-
cular and tubulointerstitial injury is not well defined. However,
the capacity of these peptides to induce extracellular matrix
synthesis [134] and the release of a variety of inflammatory
cytokines [135] suggests that they may contribute to the tubu-
lointerstitial fibrosis that characterizes late diabetic nephrop-
athy. In this formulation, renal hypertrophy is a marker for
co-incident renal injury and fibrosis rather than an etiologic
factor in this form of injury.
Conclusion
In summary, tubulointerstitial fibrosis in diabetes is an im-
portant pathologic feature of advanced diabetic nephropathy,
particularly in those patients with associated renal insuffi-
ciency. There is a clear correlation between the degree of
interstitial fibrosis and the development of a reduced GFR. The
mechanism of this relationship could be alteration in blood flow
through the fibrosed interstitium or altered hemodynamics
induced by affected vascular structures passing through the
fibrotic tissue. In addition, the direct effects on tubular function
and on tubular glomerular feedback also could be important
contributing features. One likely mediator of these effects could
be long-standing glycation of various matrix proteins which
alters their structure and function and prevents normal degra-
dation of collagen. In addition, recent evidence suggests that
glucose has a direct effect to promote collagen biosynthesis by
stimulating collagen gene expression, thus raising the possibil-
ity that the actions of diabetes to produce renal insufficiency
could be in part due to direct effects of glucose on tubular
epithelial cell matrix synthesis. A role for various growth
factors in producing renal tubular growth and hypertrophy also
seems likely. New therapeutic strategies aimed at reducing
collagen synthesis in the kidney or preventing the formation of
cross links between advanced glycation end-products of various
extracellular matrix proteins provide the possibility of altering
the natural history of diabetic nephropathy through strategies
that complement the well described benefits of anti-hyperten-
sive therapy [136, 137], and recently of reduced dietary protein
intake [138, 1391.
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